HERCULES, CA — October 8, 2008 — Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced the availability of two fast supermixes, which enable more reliable quantitative PCR (qPCR) results in less than 40 minutes.
The iTaq™ fast supermixes with ROX can be used on a variety of instruments, including ROX-dependent real-time PCR systems, and are designed to deliver maximum qPCR efficiency, sensitivity, and specificity, and a robust fluorescent signal under fast or standard cycling conditions with any real-time detection chemistry. The supermixes are preblended with hot-start iTaq DNA polymerase, optimized buffer, nucleotides, and ROX passive reference dye. The convenient one-tube formulations correct inter-well signal variation, enabling life science researchers to obtain specific, sensitive, and fast qPCR results of low abundance targets.
The iTaq fast supermix with ROX delivers superior results for gene expression analysis. Simultaneous detection of two gene targets using fluorogenic probes can be performed reliably, with no observed differences for detection of low-expressing genes in singleplex or duplex.
The iTaq SYBR® Green supermix with ROX is formulated for optimal results in real-time qPCR assays, giving excellent amplification sensitivity and specificity using fast cycling protocols. This formula yields high performance with cDNA as well as genomic and plasmid DNA templates over a broad dynamic range, achieving sensitive and specific amplification of at least seven orders of magnitude.
For more information, visit the Web at www.bio-rad.com/supermixes/
About Bio-Rad
Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs approximately 6,300 people globally and had revenues approaching $1.5 billion in 2007. For more information, visit www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2007, as updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.